Who Paid My Doc
Thomas Amatruda
Hematology & Oncology Fridley, MN Medical Doctor
NPI 1427068618 CMS profile 155438
480 Osborne Rd Ne, Suite 220, Fridley, MN 55432
General payments
$3,184
Research payments
$14,000
Ownership & investment interest
$0
Research they led as principal investigator
$3,248,892
Through program year 2023, Thomas Amatruda of Fridley, MN is reported in the CMS Open Payments database as having received $3,184 across 7 general payments and $14,000 in research payments paid to them. Separately, studies naming them as principal investigator received $3,248,892 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 79th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $3,125 | 2 | |
| 2022 | General | $13 | 1 | |
| 2022 | Research | $7,500 | 1 | |
| 2021 | General | $34 | 3 | |
| 2020 | General | $11 | 1 | |
| 2019 | Research | $6,500 | 1 |
Beside peers
- Thomas Amatruda
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Thomas Amatruda were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Thomas Amatruda | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $529 | $121–$2,516 | $163 |
| 2020 | $11 | $339 | $82–$2,213 | $114 |
| 2021 | $34 | $263 | $49–$1,965 | $132 |
| 2022 | $13 | $416 | $103–$2,395 | $149 |
| 2023 | $3,125 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $0 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
382
Drug cost
$1,034,088
Branded share of claims
38.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cabometyx Cabozantinib S-Malate | Brand | 11 | $240,694 | |
| Mektovi Binimetinib | Brand | 15 | $231,475 | |
| Braftovi Encorafenib | Brand | 15 | $225,323 | |
| Mekinist Trametinib Dimethyl Sulfoxide | Brand | 12 | $168,392 | |
| Tafinlar Dabrafenib Mesylate | Brand | 11 | $130,392 | |
| Xarelto Rivaroxaban | Brand | 43 | $33,383 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 17 | $631 | |
| Hydroxyurea | Generic | 16 | $603 | |
| Hydromorphone Hcl | Generic | 18 | $568 | |
| Prednisone | Generic | 84 | $563 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 143 billing codesPaid by Medicare
$786,111
Medicare patients
251
Services billed
38,352
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Cancer | 47% | |
| Arthritis | 36% | |
| Chronic kidney disease | 35% | |
| Diabetes | 31% | |
| Ischemic heart disease | 31% | |
| Depression | 28% | |
| Heart failure | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 15 | 5,100 | $227,351 |
| Injection, denosumab, 1 mg J0897 | Office | 12 | 2,280 | $46,166 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 11 | 37 | $5,237 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 | Office | 11 | 6,630 | $1,797 |
| Injection, granisetron hydrochloride, 100 mcg J1626 | Office | 13 | 360 | $84 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 25 | 560 | $48 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 11 | 18 | $16 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
9 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Hematology & Oncology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.